Download PDF
J Pediatr Infect Dis 2018; 13(02): 101-112
DOI: 10.1055/s-0037-1606602
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Pharmacology of Mycobacterial Drugs in Children

Jennifer L. Goldman
1   Divisions of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy Hospital, Kansas City, Missouri, United States
2   Department of Infectious Diseases, Children's Mercy Hospital, Kansas City, Missouri, United States
3   Department of Pediatrics, University of Missouri-Kansas City, School of Medicine, Kansas City, Missouri, United States
,
Susan M. Abdel-Rahman
1   Divisions of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy Hospital, Kansas City, Missouri, United States
3   Department of Pediatrics, University of Missouri-Kansas City, School of Medicine, Kansas City, Missouri, United States
› Author Affiliations
Further Information

Publication History

21 February 2017

08 March 2017

Publication Date:
05 October 2017 (online)

    Permissions and Reprints

Abstract

To effectively treat tuberculosis (TB), optimization of therapy guided by an understanding of pharmacokinetic-pharmacodynamic principles represents the strategy most likely to influence favorable patient outcomes. However, challenges are often encountered during TB treatment given the concomitant administration of multiple drugs, some with poorly defined therapeutic targets, for prolonged durations. Treatment is further complicated in children as many antitubercular drugs have not been extensively studied in the pediatric population where the impact of human development on drug disposition is relevant, but poorly understood. In this review, the pharmacokinetics (PK) of antitubercular drugs will be reviewed in the context of the pediatric population. Observed differences between adults and children with respect to TB therapy will be highlighted, and future considerations to enhance our understanding of TB drugs used in children will be explored.

Keywords

pediatrics - tuberculosis - drugs - pharmacokinetics
 

  • References

  • 1 World Health Organization. Global Tuberculosis Report 2016. Geneva, Switzerland: WHO; 2016
    Google Scholar
  • 2 World Health Organization. WHO Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. 2nd ed. Geneva, Switzerland: WHO; 2014
    Google Scholar
  • 3 Marais BJ. Improving access to tuberculosis preventive therapy and treatment for children. Int J Infect Dis 2017; 56: 122-125
    CrossrefPubMedGoogle Scholar
  • 4 Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses, 21 C.F.R. part 314, subpart H; 2016
    PubMed
  • 5 Bekker A, Schaaf HS, Seifart HI. , et al. Pharmacokinetics of isoniazid in low-birth-weight and premature infants. Antimicrob Agents Chemother 2014; 58 (04) 2229-2234
    CrossrefPubMedGoogle Scholar
  • 6 Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999; 3 (08) 703-710
    PubMedGoogle Scholar
  • 7 Pouplin T, Bang ND, Toi PV. , et al. Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis. BMC Infect Dis 2016; 16: 144
    CrossrefPubMedGoogle Scholar
  • 8 Roy V, Gupta D, Gupta P, Sethi GR, Mishra TK. Pharmacokinetics of isoniazid in moderately malnourished children with tuberculosis. Int J Tuberc Lung Dis 2010; 14 (03) 374-376
    PubMedGoogle Scholar
  • 9 Seth V, Beotra A, Seth SD. , et al. Serum concentrations of rifampicin and isoniazid in tuberculosis. Indian Pediatr 1993; 30 (09) 1091-1098
    PubMedGoogle Scholar
  • 10 Thee S, Detjen AA, Wahn U, Magdorf K. Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis. Scand J Infect Dis 2010; 42 (04) 294-298
    CrossrefPubMedGoogle Scholar
  • 11 Kiser JJ, Zhu R, DʼArgenio DZ. , et al. Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants. Ther Drug Monit 2012; 34 (04) 446-451
    CrossrefPubMedGoogle Scholar
  • 12 Thee S, Seddon JA, Donald PR. , et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother 2011; 55 (12) 5560-5567
    CrossrefPubMedGoogle Scholar
  • 13 Verhagen LM, López D, Hermans PW. , et al. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. Trop Med Int Health 2012; 17 (12) 1449-1456
    CrossrefPubMedGoogle Scholar
  • 14 Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349 (12) 1157-1167
    CrossrefPubMedGoogle Scholar
  • 15 Keller GA, Fabian L, Gomez M, Gonzalez CD, Diez RA, Di Girolamo G. Age-distribution and genotype-phenotype correlation for N-acetyltransferase in Argentine children under isoniazid treatment. Int J Clin Pharmacol Ther 2014; 52 (04) 292-302
    CrossrefPubMedGoogle Scholar
  • 16 Ramachandran G, Hemanth Kumar AK, Bhavani PK. , et al. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children. Int J Tuberc Lung Dis 2013; 17 (06) 800-806
    CrossrefPubMedGoogle Scholar
  • 17 Kwara A, Enimil A, Gillani FS. , et al. Pharmacokinetics of first-line antituberculosis drugs using WHO revised dosage in children with tuberculosis with and without HIV coinfection. J Pediatric Infect Dis Soc 2016; 5 (04) 356-365
    CrossrefPubMedGoogle Scholar
  • 18 Gumbo T, Louie A, Deziel MR. , et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51 (11) 3781-3788
    CrossrefPubMedGoogle Scholar
  • 19 Nahata MC, Morosco RS, Hipple TF. Effect of preparation method and storage on rifampin concentration in suspensions. Ann Pharmacother 1994; 28 (02) 182-185
    CrossrefPubMedGoogle Scholar
  • 20 Bekker A, Schaaf HS, Draper HR. , et al. Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines. Antimicrob Agents Chemother 2016; 60 (04) 2171-2179
    CrossrefPubMedGoogle Scholar
  • 21 McIlleron H, Hundt H, Smythe W. , et al. Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes. Int J Tuberc Lung Dis 2016; 20 (07) 915-919
    CrossrefPubMedGoogle Scholar
  • 22 Donald PR, Maritz JS, Diacon AH. The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children. Tuberculosis (Edinb) 2011; 91 (03) 196-207
    CrossrefPubMedGoogle Scholar
  • 23 Koup JR, Williams-Warren J, Viswanathan CT, Weber A, Smith AL. Pharmacokinetics of rifampin in children. II. Oral bioavailability. Ther Drug Monit 1986; 8 (01) 17-22
    CrossrefPubMedGoogle Scholar
  • 24 Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3 (02) 108-127
    CrossrefPubMedGoogle Scholar
  • 25 Hussels H, Kroening U, Magdorf K. Ethambutol and rifampicin serum levels in children: second report on the combined administration of ethambutol and rifampicin. Pneumonologie 1973; 149 (01) 31-38
    CrossrefPubMedGoogle Scholar
  • 26 Tan TQ, Mason Jr EO, Ou CN, Kaplan SL. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother 1993; 37 (11) 2401-2406
    CrossrefPubMedGoogle Scholar
  • 27 Thee S, Detjen A, Wahn U, Magdorf K. Rifampicin serum levels in childhood tuberculosis. Int J Tuberc Lung Dis 2009; 13 (09) 1106-1111
    PubMedGoogle Scholar
  • 28 Agrawal S, Panchagnula R. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. Biopharm Drug Dispos 2005; 26 (08) 321-334
    CrossrefPubMedGoogle Scholar
  • 29 Agunod M, Yamaguchi N, Lopez R, Luhby AL, Glass GB. Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am J Dig Dis 1969; 14 (06) 400-414
    CrossrefPubMedGoogle Scholar
  • 30 Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999; 115 (01) 12-18
    CrossrefPubMedGoogle Scholar
  • 31 Polasa K, Krishnaswamy K. Effect of food on bioavailability of rifampicin. J Clin Pharmacol 1983; 23 (10) 433-437
    CrossrefPubMedGoogle Scholar
  • 32 Siegler DI, Bryant M, Burley DM, Citron KM, Standen SM. Effect of meals on rifampicin absorption. Lancet 1974; 2 (7874): 197-198
    PubMedGoogle Scholar
  • 33 McCracken Jr GH, Ginsburg CM, Zweighaft TC, Clahsen J. Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis against Haemophilus influenzae type b disease. Pediatrics 1980; 66 (01) 17-21
    PubMedGoogle Scholar
  • 34 Regazzi M, Carvalho AC, Villani P, Matteelli A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin Pharmacokinet 2014; 53 (06) 489-507
    CrossrefPubMedGoogle Scholar
  • 35 Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9 (06) 511-544
    CrossrefPubMedGoogle Scholar
  • 36 Nahata MC, Fan-Havard P, Barson WJ, Bartkowski HM, Kosnik EJ. Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements. Eur J Clin Pharmacol 1990; 38 (05) 515-517
    CrossrefPubMedGoogle Scholar
  • 37 Koup JR, Williams-Warren J, Weber A, Smith AL. Pharmacokinetics of rifampin in children. I. Multiple dose intravenous infusion. Ther Drug Monit 1986; 8 (01) 11-16
    CrossrefPubMedGoogle Scholar
  • 38 Ramachandran G, Kumar AK, Kannan T. , et al. Low serum concentrations of rifampicin and pyrazinamide associated with poor treatment outcomes in children with tuberculosis related to HIV status. Pediatr Infect Dis J 2016; 35 (05) 530-534
    CrossrefPubMedGoogle Scholar
  • 39 Hiruy H, Rogers Z, Mbowane C. , et al. Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. J Antimicrob Chemother 2015; 70 (04) 1115-1123
    PubMedGoogle Scholar
  • 40 Antwi S, Yang H, Enimil A. , et al. Pharmacokinetics of the first-line antituberculosis drugs in Ghanaian children with tuberculosis with or without HIV coinfection. Antimicrob Agents Chemother 2017; 61 (02) 61
    PubMedGoogle Scholar
  • 41 Mlotha R, Waterhouse D, Dzinjalamala F. , et al. Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol. J Antimicrob Chemother 2015; 70 (06) 1798-1803
    CrossrefPubMedGoogle Scholar
  • 42 Arya A, Roy V, Lomash A, Kapoor S, Khanna A, Rangari G. Rifampicin pharmacokinetics in children under the Revised National Tuberculosis Control Programme, India, 2009. Int J Tuberc Lung Dis 2015; 19 (04) 440-445
    CrossrefPubMedGoogle Scholar
  • 43 Mukherjee A, Velpandian T, Singla M, Kanhiya K, Kabra SK, Lodha R. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. BMC Infect Dis 2015; 15: 126
    CrossrefPubMedGoogle Scholar
  • 44 Ramachandran G, Kumar AK, Bhavani PK. , et al. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. Antimicrob Agents Chemother 2015; 59 (02) 1162-1167
    CrossrefPubMedGoogle Scholar
  • 45 Savic RM, Ruslami R, Hibma JE. , et al. Pediatric tuberculous meningitis: model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. Clin Pharmacol Ther 2015; 98 (06) 622-629
    CrossrefPubMedGoogle Scholar
  • 46 Schaaf HS, Garcia-Prats AJ, Donald PR. Antituberculosis drugs in children. Clin Pharmacol Ther 2015; 98 (03) 252-265
    CrossrefPubMedGoogle Scholar
  • 47 Zvada SP, Denti P, Donald PR. , et al. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. J Antimicrob Chemother 2014; 69 (05) 1339-1349
    CrossrefPubMedGoogle Scholar
  • 48 Dooley KE, Bliven-Sizemore EE, Weiner M. , et al. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther 2012; 91 (05) 881-888
    CrossrefPubMedGoogle Scholar
  • 49 Weiner M, Bock N, Peloquin CA. , et al; Tuberculosis Trials Consortium. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 2004; 169 (11) 1191-1197
    CrossrefPubMedGoogle Scholar
  • 50 Chan SL, Yew WW, Porter JH. , et al. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J Antimicrob Agents 1994; 3 (04) 267-274
    CrossrefPubMedGoogle Scholar
  • 51 Zvada SP, Van Der Walt JS, Smith PJ. , et al. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother 2010; 54 (08) 3390-3394
    CrossrefPubMedGoogle Scholar
  • 52 Reith K, Keung A, Toren PC, Cheng L, Eller MG, Weir SJ. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab Dispos 1998; 26 (08) 732-738
    PubMedGoogle Scholar
  • 53 Blake MJ, Abdel-Rahman SM, Jacobs RF, Lowery NK, Sterling TR, Kearns GL. Pharmacokinetics of rifapentine in children. Pediatr Infect Dis J 2006; 25 (05) 405-409
    CrossrefPubMedGoogle Scholar
  • 54 Marshall JD, Abdel-Rahman S, Johnson K, Kauffman RE, Kearns GL. Rifapentine pharmacokinetics in adolescents. Pediatr Infect Dis J 1999; 18 (10) 882-888
    CrossrefPubMedGoogle Scholar
  • 55 Weiner M, Savic RM, Kenzie WR. , et al; Tuberculosis Trials Consortium PREVENT TB Pharmacokinetic Group. Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Pediatric Infect Dis Soc 2014; 3 (02) 132-145
    CrossrefPubMedGoogle Scholar
  • 56 Skinner MH, Blaschke TF. Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet 1995; 28 (02) 115-125
    CrossrefPubMedGoogle Scholar
  • 57 Skinner MH, Hsieh M, Torseth J. , et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 1989; 33 (08) 1237-1241
    CrossrefPubMedGoogle Scholar
  • 58 Moultrie H, McIlleron H, Sawry S. , et al. Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. J Antimicrob Chemother 2015; 70 (02) 543-549
    CrossrefPubMedGoogle Scholar
  • 59 Mycobutin – rifaputin capsules [package insert]. New York, NY: Pharmacia & Upjohn; 2010
    Google Scholar
  • 60 Donald PR, Maritz JS, Diacon AH. Pyrazinamide pharmacokinetics and efficacy in adults and children. Tuberculosis (Edinb) 2012; 92 (01) 1-8
    CrossrefPubMedGoogle Scholar
  • 61 Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997; 41 (12) 2670-2679
    CrossrefPubMedGoogle Scholar
  • 62 Thee S, Detjen A, Wahn U, Magdorf K. Pyrazinamide serum levels in childhood tuberculosis. Int J Tuberc Lung Dis 2008; 12 (09) 1099-1101
    PubMedGoogle Scholar
  • 63 Gupta P, Roy V, Sethi GR, Mishra TK. Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses. Br J Clin Pharmacol 2008; 65 (03) 423-427
    CrossrefPubMedGoogle Scholar
  • 64 Lacroix C, Hoang TP, Nouveau J. , et al. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol 1989; 36 (04) 395-400
    CrossrefPubMedGoogle Scholar
  • 65 Arya DS, Ojha SK, Semwal OP, Nandave M. Pharmacokinetics of pyrazinamide in children with primary progressive disease of lungs. Indian J Med Res 2008; 128 (05) 611-615
    PubMedGoogle Scholar
  • 66 Roy V, Tekur U, Chopra K. Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis. Int J Tuberc Lung Dis 1999; 3 (02) 133-137
    PubMedGoogle Scholar
  • 67 Zhu M, Starke JR, Burman WJ. , et al. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 2002; 22 (06) 686-695
    CrossrefPubMedGoogle Scholar
  • 68 Zhu M, Burman WJ, Starke JR. , et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis 2004; 8 (11) 1360-1367
    PubMedGoogle Scholar
  • 69 Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 1999; 43 (03) 568-572
    CrossrefPubMedGoogle Scholar
  • 70 Jusko WJ, Gretch M. Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev 1976; 5 (01) 43-140
    CrossrefPubMedGoogle Scholar
  • 71 Lee CS, Gambertoglio JG, Brater DC, Benet LZ. Kinetics of oral ethambutol in the normal subject. Clin Pharmacol Ther 1977; 22 (5 Pt 1): 615-621
    CrossrefPubMedGoogle Scholar
  • 72 Levy M, Rigaudière F, de Lauzanne A. , et al. Ethambutol-related impaired visual function in childrens less than 5 years of age treated for a mycobacterial infection: diagnosis and evolution. Pediatr Infect Dis J 2015; 34 (04) 346-350
    CrossrefPubMedGoogle Scholar
  • 73 Adcock JD, Hettig RA. Absorption, distribution and excretion of streptomycin. Arch Intern Med (Chic) 1946; 77: 179-195
    CrossrefPubMedGoogle Scholar
  • 74 Briedis DJ, Robson HG. Cerebrospinal fluid penetration of amikacin. Antimicrob Agents Chemother 1978; 13 (06) 1042-1043
    CrossrefPubMedGoogle Scholar
  • 75 Assael BM, Parini R, Rusconi F, Cavanna G. Influence of intrauterine maturation on the pharmacokinetics of amikacin in the neonatal period. Pediatr Res 1982; 16 (10) 810-815
    CrossrefPubMedGoogle Scholar
  • 76 Beachler CW, Speer ME, Mason Jr EO, Yow MD. Pharmacology of kanamycin in the newborn. South Med J 1982; 75 (03) 301-305
    CrossrefPubMedGoogle Scholar
  • 77 Bolme P, Eriksson M, Habte D, Paalzow L. Pharmacokinetics of streptomycin in Ethiopian children with tuberculosis and of different nutritional status. Eur J Clin Pharmacol 1988; 33 (06) 647-649
    CrossrefPubMedGoogle Scholar
  • 78 Herngren L, Boréus LO, Jalling B, Lagercrantz R. Pharmacokinetic aspects of streptomycin treatment of neonatal septicemia. Scand J Infect Dis 1977; 9 (04) 301-308
    CrossrefPubMedGoogle Scholar
  • 79 Hieber JP, Nelson JD. Reevaluation of kanamycin dosage in infants and children. Antimicrob Agents Chemother 1976; 9 (06) 899-902
    CrossrefPubMedGoogle Scholar
  • 80 Howard JB, McCracken Jr GH. Reappraisal of kanamycin usage in neonates. J Pediatr 1975; 86 (06) 949-956
    CrossrefPubMedGoogle Scholar
  • 81 Marik PE, Havlik I, Monteagudo FS, Lipman J. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens. J Antimicrob Chemother 1991; 27 (Suppl C): 81-89
    PubMedGoogle Scholar
  • 82 Padovani EM, Pistolesi C, Fanos V, Messori A, Martini N. Pharmacokinetics of amikacin in neonates. Dev Pharmacol Ther 1993; 20 (3-4): 167-173
    CrossrefPubMedGoogle Scholar
  • 83 Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA. Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy 2001; 21 (09) 1037-1045
    CrossrefPubMedGoogle Scholar
  • 84 Doluisio JT, Dittert LW, LaPiana JC. Pharmacokinetics of kanamycin following intramuscular administration. J Pharmacokinet Biopharm 1973; 1: 253-265
    CrossrefPubMedGoogle Scholar
  • 85 Plantier J, Forrey AW, O'Neill MA, Blair AD, Christopher TG, Cutler RE. Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay. J Infect Dis 1976; 134 (SUPPL): S323-S330
    CrossrefPubMedGoogle Scholar
  • 86 Eriksson M, Bolme P, Habte D, Paalzow L. INH and streptomycin in Ethiopian children with tuberculosis and different nutritional status. Acta Paediatr Scand 1988; 77 (06) 890-894
    CrossrefPubMedGoogle Scholar
  • 87 McCracken Jr GH, Threlkeld N, Thomas ML. Intravenous administration of kanamycin and gentamicin in newborn infants. Pediatrics 1977; 60 (04) 463-466
    PubMedGoogle Scholar
  • 88 Black HR, Griffith RS, Peabody AM. Absorption, excretion and metabolism of capreomycin in normal and diseased states. Ann N Y Acad Sci 1966; 135 (02) 974-982
    CrossrefPubMedGoogle Scholar
  • 89 Chien S, Wells TG, Blumer JL. , et al. Levofloxacin pharmacokinetics in children. J Clin Pharmacol 2005; 45 (02) 153-160
    CrossrefPubMedGoogle Scholar
  • 90 Thee S, Garcia-Prats AJ, Draper HR. , et al. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Clin Infect Dis 2015; 60 (04) 549-556
    CrossrefPubMedGoogle Scholar
  • 91 Thee S, Garcia-Prats AJ, McIlleron HM. , et al. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. Antimicrob Agents Chemother 2014; 58 (05) 2948-2951
    CrossrefPubMedGoogle Scholar
  • 92 Levofloxacin drug insert. 2008. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf
    PubMed
  • 93 Stass H, Böttcher MF, Ochmann K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Clin Pharmacokinet 2001; 40 (Suppl. 01) 39-48
    CrossrefPubMedGoogle Scholar
  • 94 Capparelli EV, Reed MD, Bradley JS. , et al. Pharmacokinetics of gatifloxacin in infants and children. Antimicrob Agents Chemother 2005; 49 (03) 1106-1112
    CrossrefPubMedGoogle Scholar
  • 95 Tachibana M, Tanaka M, Masubuchi Y, Horie T. Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes. Drug Metab Dispos 2005; 33 (06) 803-811
    CrossrefPubMedGoogle Scholar
  • 96 Strassburg CP, Strassburg A, Kneip S. , et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002; 50 (02) 259-265
    CrossrefPubMedGoogle Scholar
  • 97 Patel K, Goldman JL. Safety concerns surrounding quinolone use in children. J Clin Pharmacol 2016; 56 (09) 1060-1075
    CrossrefPubMedGoogle Scholar
  • 98 Thee S, Garcia-Prats AJ, Donald PR, Hesseling AC, Schaaf HS. Fluoroquinolones for the treatment of tuberculosis in children. Tuberculosis (Edinb) 2015; 95 (03) 229-245
    CrossrefPubMedGoogle Scholar
  • 99 Soderhjelm L. Serum para-aminosalicylic acid following oral ingestion in children. Tex Rep Biol Med 1949; 7 (03) 471-479
    PubMedGoogle Scholar
  • 100 Liwa AC, Schaaf HS, Rosenkranz B, Seifart HI, Diacon AH, Donald PR. Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation. J Trop Pediatr 2013; 59 (02) 90-94
    CrossrefPubMedGoogle Scholar
  • 101 Peloquin CA, Zhu M, Adam RD, Singleton MD, Nix DE. Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. Ann Pharmacother 2001; 35 (11) 1332-1338
    CrossrefPubMedGoogle Scholar
  • 102 Way EL, Smith PK. , et al. The absorption, distribution, excretion and fate of para-aminosalicylic acid. J Pharmacol Exp Ther 1948; 93 (03) 368-382
    PubMedGoogle Scholar
  • 103 Paser aminosalicylic acid granules delayed release [package insert]. Princeton NJ: Jacobus Pharmaceutical Company Inc; 1996
    Google Scholar
  • 104 Lehmann J. The role of the metabolism of p-aminosalicylic acid (PAS) in the treatment of tuberculosis. Interaction with the metabolism of isonicotinic acid hydrazide (INH) and the synthesis of cholesterol. Scand J Respir Dis 1969; 50 (03) 169-185
    PubMedGoogle Scholar
  • 105 Sy SK, de Kock L, Diacon AH. , et al. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis. Antimicrob Agents Chemother 2015; 59 (07) 4129-4138
    CrossrefPubMedGoogle Scholar
  • 106 Curci C. Pharmacological considerations on cycloserine. Scand J Respir Dis Suppl 1970; 71: 51-60
    PubMedGoogle Scholar
  • 107 Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy 2001; 21 (08) 891-897
    CrossrefPubMedGoogle Scholar
  • 108 Niemistö M. The influence of sustained release effect on cycloserine concentration in serum. Scand J Respir Dis Suppl 1970; 71: 64-67
    PubMedGoogle Scholar
  • 109 Zítková L, Tousek J. Pharmacokinetics of cycloserine and terizidone. A comparative study. Chemotherapy 1974; 20 (01) 18-28
    CrossrefPubMedGoogle Scholar
  • 110 Battaglia B, Kaufman I, Lyons HA, Marsh W. Toxicity of cycloserine combined with isoniazid in the treatment of tuberculosis in children. Am Rev Respir Dis 1961; 83: 751-752
    PubMedGoogle Scholar
  • 111 Seromycin cycloserine capsule [package insert]. Indianapolis, IN: Eli Lilly and Company; 2005
    Google Scholar
  • 112 Conte JE, Barriere SL. Manual of Antibiotics and Infectious Diseases. 5th ed. Philadelphia, PA: Lea & Febiger; 1984
    Google Scholar
  • 113 Auclair B, Nix DE, Adam RD, James GT, Peloquin CA. Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. Antimicrob Agents Chemother 2001; 45 (03) 810-814
    CrossrefPubMedGoogle Scholar
  • 114 Lee HW, Kim DW, Park JH. , et al. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13 (09) 1161-1166
    PubMedGoogle Scholar
  • 115 Thee S, Garcia-Prats AJ, Donald PR, Hesseling AC, Schaaf HS. A review of the use of ethionamide and prothionamide in childhood tuberculosis. Tuberculosis (Edinb) 2016; 97: 126-136
    CrossrefPubMedGoogle Scholar
  • 116 Peloquin CA, James GT, McCarthy E, Goble M. Pharmacokinetic evaluation of ethionamide suppositories. Pharmacotherapy 1991; 11 (05) 359-363
    PubMedGoogle Scholar
  • 117 Jenner PJ, Smith SE. Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages. Lepr Rev 1987; 58 (01) 31-37
    PubMedGoogle Scholar
  • 118 Conte Jr JE, Golden JA, McQuitty M, Kipps J, Lin ET, Zurlinden E. Effects of AIDS and gender on steady-state plasma and intrapulmonary ethionamide concentrations. Antimicrob Agents Chemother 2000; 44 (05) 1337-1341
    CrossrefPubMedGoogle Scholar
  • 119 Donald PR, Seifart HI. Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis. J Pediatr 1989; 115 (03) 483-486
    CrossrefPubMedGoogle Scholar
  • 120 Hughes IE, Smith H. Ethionamide: its passage into the cerebrospinal fluid in man. Lancet 1962; 1 (7230): 616-617
    PubMedGoogle Scholar
  • 121 Henderson MC, Siddens LK, Morré JT, Krueger SK, Williams DE. Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes. Toxicol Appl Pharmacol 2008; 233 (03) 420-427
    CrossrefPubMedGoogle Scholar
  • 122 Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 2002; 51 (02) 236-243
    CrossrefPubMedGoogle Scholar
  • 123 Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62 (15) 2169-2183
    CrossrefPubMedGoogle Scholar
  • 124 Thee S, Seifart HI, Rosenkranz B. , et al. Pharmacokinetics of ethionamide in children. Antimicrob Agents Chemother 2011; 55 (10) 4594-4600
    CrossrefPubMedGoogle Scholar
  • 125 Mathur A, Venkatesan K, Bharadwaj VP, Ramu G. Evaluation of effectiveness of clofazimine therapy. I. Monitoring of absorption of clofazimine from gastrointestinal tract. Indian J Lepr 1985; 57 (01) 146-148
    PubMedGoogle Scholar
  • 126 Nix DE, Adam RD, Auclair B, Krueger TS, Godo PG, Peloquin CA. Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb) 2004; 84 (06) 365-373
    CrossrefPubMedGoogle Scholar
  • 127 Jadhav MV, Sathe AG, Deore SS, Patil PG, Joshi NG. Tissue concentration, systemic distribution and toxicity of clofazimine--an autopsy study. Indian J Pathol Microbiol 2004; 47 (02) 281-283
    PubMedGoogle Scholar
  • 128 Mansfield RE. Tissue concentrations of clofazimine (B663) in man. Am J Trop Med Hyg 1974; 23 (06) 1116-1119
    CrossrefPubMedGoogle Scholar
  • 129 Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16 (04) 447-454
    CrossrefPubMedGoogle Scholar
  • 130 Abdel-Rahman SM, Kearns GL. An update on the oxazolidinone antibiotics. Pediatr Infect Dis J 1999; 18 (12) 1101-1102
    CrossrefPubMedGoogle Scholar
  • 131 Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42 (13) 1129-1140
    CrossrefPubMedGoogle Scholar
  • 132 Kearns GL, Jungbluth GL, Abdel-Rahman SM. , et al; Pediatric Pharmacology Research Unit Network. Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther 2003; 74 (05) 413-422
    CrossrefPubMedGoogle Scholar
  • 133 Andreas M, Zeitlinger M, Wisser W. , et al. Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting. Eur J Cardiothorac Surg 2015; 48 (05) 758-764
    CrossrefPubMedGoogle Scholar
  • 134 Eslam RB, Burian A, Vila G. , et al. Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection. J Clin Pharmacol 2014; 54 (09) 1058-1062
    CrossrefPubMedGoogle Scholar
  • 135 Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003; 51 (06) 1431-1434
    CrossrefPubMedGoogle Scholar
  • 136 Myrianthefs P, Markantonis SL, Vlachos K. , et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006; 50 (12) 3971-3976
    CrossrefPubMedGoogle Scholar
  • 137 Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138 (02) 135-142
    CrossrefPubMedGoogle Scholar
  • 138 Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22 (9, Suppl): S153-S157
    CrossrefPubMedGoogle Scholar
  • 139 Swaminathan A, du Cros P, Seddon JA. , et al. Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications. Int J Tuberc Lung Dis 2016; 20 (04) 474-478
    CrossrefPubMedGoogle Scholar
  • 140 Rose PC, Hallbauer UM, Seddon JA, Hesseling AC, Schaaf HS. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis 2012; 16 (12) 1588-1593
    CrossrefPubMedGoogle Scholar
  • 141 Garcia-Prats AJ, Rose PC, Hesseling AC, Schaaf HS. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. Tuberculosis (Edinb) 2014; 94 (02) 93-104
    CrossrefPubMedGoogle Scholar
  • 142 Chintu C, Luo C, Bhat G, Raviglione M, DuPont H, Zumla A. Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I. Arch Dis Child 1993; 68 (05) 665-668
    CrossrefPubMedGoogle Scholar
  • 143 Ellard GA, Dickinson JM, Gammon PT, Mitchison DA. Serum concentrations and antituberculosis activity of thiacetazone. Tubercle 1974; 55 (01) 41-54
    CrossrefPubMedGoogle Scholar
  • 144 Jenner PJ, Ellard GA, Swai OB. A study of thiacetazone blood levels and urinary excretion in man, using high performance liquid chromatography. Lepr Rev 1984; 55 (02) 121-128
    PubMedGoogle Scholar
  • 145 Peloquin CA, Nitta AT, Berning SE, Iseman MD, James GT. Pharmacokinetic evaluation of thiacetazone. Pharmacotherapy 1996; 16 (05) 735-741
    PubMedGoogle Scholar
  • 146 Francois AA, Nishida CR, de Montellano PR, Phillips IR, Shephard EA. Human flavin-containing monooxygenase 2.1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide. Drug Metab Dispos 2009; 37 (01) 178-186
    CrossrefPubMedGoogle Scholar
  • 147 Hoagland D, Zhao Y, Lee RE. Advances in drug discovery and development for pediatric tuberculosis. Mini Rev Med Chem 2016; 16 (06) 481-497
    CrossrefPubMedGoogle Scholar
  • 148 Andries K, Verhasselt P, Guillemont J. , et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307 (5707): 223-227
    CrossrefPubMedGoogle Scholar
  • 149 Clinical Trials. Gov. Available at: https://www.clinicaltrials.gov/ct2/results?term=bedaquiline&pg=1 . Last accessed December 5, 2016
    PubMed
  • 150 van Heeswijk RP, Dannemann B, Hoetelmans RM. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother 2014; 69 (09) 2310-2318
    CrossrefPubMedGoogle Scholar
  • 151 Tmc-207. Tuberculosis (Edinb) 2008; 88 (02) 168-169
    CrossrefPubMedGoogle Scholar
  • 152 Matteelli A, Carvalho AC, Dooley KE, Kritski A. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010; 5 (06) 849-858
    CrossrefPubMedGoogle Scholar
  • 153 Diacon AH, Donald PR, Pym A. , et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56 (06) 3271-3276
    CrossrefPubMedGoogle Scholar
  • 154 The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents interim policy guidance. World Health Organization. 2016 . Available at: https://www.ghdonline.org/uploads/Delamanid_guideline_child-adol_Oct16.pdf
    PubMed
  • 155 Tadolini M, Garcia-Prats AJ, D'Ambrosio L. , et al. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. Eur Respir J 2016; 48 (03) 938-943
    CrossrefPubMedGoogle Scholar